Log In Sign up
The largest database of trusted experimental protocols

Pcdna3.1 ev

Manufactured by GenePharma
Visit Supplier
Sourced in China

PcDNA3.1 (EV) is a plasmid vector that can be used for the expression of proteins in mammalian cells. It contains a strong viral promoter, a multiple cloning site for the insertion of the gene of interest, and a selection marker for the identification of transfected cells.

Automatically generated - may contain errors

Lab products found in correlation

Pcdna3, by Roche (1 mentions) X tremegene hp dna transfection reagent, by Roche (1 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions)

Spelling variants of this product

PcDNA3.1 (221 citations)

2 protocols using pcdna3.1 ev

1

STAT1 Overexpression in Liver Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
SMMC7721 and HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % fetal calf serum at 37 °C and 5 % CO2. The plasmids of pcDNA3.1 (EV) and pcDNA3.1-STAT1 were obtained from GenePharma. pcDNA3.1 (EV) and pcDNA3.1-STAT1 were transfected into SMMC7721 and HepG2 cells at 70 % confluence using X-tremeGENE HP DNA transfection reagent (Roche, Mannheim, Germany) according to the manufacturer’s protocol. Cells were transfected for 48 h in 6-well plates and then analyzed for flow cytometry, MTT assay, western blot and qRT-PCR.
Chen J., Wang H., Wang J., Huang S, & Zhang W. (2015). STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7. Cancer Cell International, 15, 111.
+ Open protocol
+ Expand
2

Mcl-1 Overexpression and PTEN Silencing

Check if the same lab product or an alternative is used in the 5 most similar protocols
The empty vector (pcDNA3.1, EV) and pcDNA3.1-Mcl-1 (OV Mcl-1) were obtained from GenePharma (China). The myr-Akt vector was purchased from Addgene (USA). siRNA against PTEN (si-PTEN) and negative scramble control (si-NC) were purchased from RioBio Ltd. (China). The transfection was conducted using lipofectamine 2000 (Life Technologies, USA) according to the manufacturer's instructions. The transfection efficiency was evaluated using western blotting.
Shang X., Na X., Wang L., Yang Z, & Ren P. (2022). Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells. Evidence-based Complementary and Alternative Medicine : eCAM, 2022, 8110796.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!